NI200600217A - Derivados de imidazol utilizados como inhibidores de tafia - Google Patents

Derivados de imidazol utilizados como inhibidores de tafia

Info

Publication number
NI200600217A
NI200600217A NI200600217A NI200600217A NI200600217A NI 200600217 A NI200600217 A NI 200600217A NI 200600217 A NI200600217 A NI 200600217A NI 200600217 A NI200600217 A NI 200600217A NI 200600217 A NI200600217 A NI 200600217A
Authority
NI
Nicaragua
Prior art keywords
derivatives used
tafia inhibitors
imidazol derivatives
inhibitors
compounds
Prior art date
Application number
NI200600217A
Other languages
English (en)
Inventor
Christopher Kallus
Holger Heitsch
Andreas Lindenschmidt
Sven Grueneberg
Szillat Hauke
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200600217(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NI200600217A publication Critical patent/NI200600217A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de la fórmula (I) que son inhibidores del inhibidor de la fibrinolisis activable por trombina activado. Los compuestos de fórmula (I) resultan adecuados para producir medicamentos para la profilaxis y el tratamiento de enfermedades acompañadas de trombosis, embolismos, hipercoagulabilidad o cambios fibróticos.
NI200600217A 2004-04-22 2006-09-20 Derivados de imidazol utilizados como inhibidores de tafia NI200600217A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla

Publications (1)

Publication Number Publication Date
NI200600217A true NI200600217A (es) 2008-06-17

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200600217A NI200600217A (es) 2004-04-22 2006-09-20 Derivados de imidazol utilizados como inhibidores de tafia

Country Status (35)

Country Link
EP (2) EP1864979B1 (es)
JP (1) JP4939401B2 (es)
KR (1) KR101162047B1 (es)
CN (1) CN100572376C (es)
AR (1) AR053302A1 (es)
AT (2) ATE386737T1 (es)
AU (1) AU2005238144B2 (es)
BR (1) BRPI0510159A (es)
CA (1) CA2563401C (es)
CR (1) CR8650A (es)
CY (1) CY1108087T1 (es)
DE (2) DE102004020186A1 (es)
DK (1) DK1740569T3 (es)
EC (1) ECSP066941A (es)
ES (1) ES2299026T3 (es)
HK (1) HK1101823A1 (es)
HR (1) HRP20080099T3 (es)
IL (1) IL178672A (es)
MA (1) MA28543B1 (es)
MY (1) MY140903A (es)
NI (1) NI200600217A (es)
NO (1) NO20065320L (es)
NZ (1) NZ550757A (es)
PE (1) PE20060172A1 (es)
PL (1) PL1740569T3 (es)
PT (1) PT1740569E (es)
RS (1) RS50553B (es)
RU (1) RU2375356C2 (es)
SI (1) SI1740569T1 (es)
TN (1) TNSN06341A1 (es)
TW (1) TWI359016B (es)
UA (1) UA87306C2 (es)
UY (1) UY28868A1 (es)
WO (1) WO2005105781A1 (es)
ZA (1) ZA200607668B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007327959B2 (en) * 2006-12-06 2013-08-01 Sanofi-Aventis Urea and sulfamide derivatives as tafia inhibitors
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
MX2009008777A (es) * 2007-02-13 2009-08-25 Schering Corp Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
CA2726554C (en) 2008-06-06 2015-02-24 Sanofi-Aventis Macrocyclic urea and sulfamide derivatives as inhibitors of tafia
NZ592764A (en) 2008-10-29 2012-08-31 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
JP5706397B2 (ja) * 2009-05-15 2015-04-22 サノフイ ＴＡＦＩａの阻害剤として有用な化合物の製造方法
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2775840C (en) 2009-10-01 2018-02-06 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
PL2548871T3 (pl) 2010-03-18 2017-12-29 Daiichi Sankyo Company, Limited Pochodne imidazolu podstawionego cykloalkilem
BR112012023412A2 (pt) 2010-03-18 2018-05-08 Daiichi Sankyo Company, Limited composto, drogra farmacêutica, inibidor de tafia, promotor de fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, e, uso de um composto.
MX2013004193A (es) 2010-11-11 2013-06-05 Sanofi Sa Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9102657B2 (en) * 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
EP2782574B1 (de) 2011-11-25 2016-03-30 Sanofi Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
WO2014198620A1 (en) * 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
JPWO2017170460A1 (ja) 2016-03-29 2019-02-07 第一三共株式会社 炎症性腸疾患治療剤
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
WO2003061653A1 (en) 2002-01-22 2003-07-31 Pfizer Limited 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
ATE386737T1 (de) 2008-03-15
DE102004020186A1 (de) 2005-11-17
DE502005002927D1 (de) 2008-04-03
TW200602325A (en) 2006-01-16
HRP20080099T3 (en) 2008-03-31
CA2563401C (en) 2012-08-07
AU2005238144A1 (en) 2005-11-10
CR8650A (es) 2007-12-04
RS50553B (sr) 2010-05-07
CN1950357A (zh) 2007-04-18
JP2007533672A (ja) 2007-11-22
SI1740569T1 (sl) 2008-06-30
ES2299026T3 (es) 2008-05-16
IL178672A (en) 2011-08-31
NZ550757A (en) 2010-06-25
DK1740569T3 (da) 2008-06-02
KR101162047B1 (ko) 2012-07-04
TNSN06341A1 (en) 2008-02-22
PE20060172A1 (es) 2006-03-31
UY28868A1 (es) 2005-11-30
PL1740569T3 (pl) 2008-07-31
UA87306C2 (en) 2009-07-10
KR20070007346A (ko) 2007-01-15
RU2375356C2 (ru) 2009-12-10
MY140903A (en) 2010-01-29
CN100572376C (zh) 2009-12-23
WO2005105781A1 (de) 2005-11-10
RU2006141246A (ru) 2008-06-10
CA2563401A1 (en) 2005-11-10
AU2005238144B2 (en) 2010-08-26
BRPI0510159A (pt) 2007-10-02
HK1101823A1 (en) 2007-10-26
EP1740569B1 (de) 2008-02-20
IL178672A0 (en) 2007-02-11
EP1864979A1 (de) 2007-12-12
ZA200607668B (en) 2008-03-26
NO20065320L (no) 2007-01-12
EP1740569A1 (de) 2007-01-10
PT1740569E (pt) 2008-03-31
EP1864979B1 (de) 2011-09-07
JP4939401B2 (ja) 2012-05-23
MA28543B1 (fr) 2007-04-03
TWI359016B (en) 2012-03-01
AR053302A1 (es) 2007-05-02
ATE523505T1 (de) 2011-09-15
CY1108087T1 (el) 2014-02-12
ECSP066941A (es) 2006-12-20

Similar Documents

Publication Publication Date Title
NI200600217A (es) Derivados de imidazol utilizados como inhibidores de tafia
CO6321271A2 (es) Derivados de urea macrociclicos y de sulfamida como inhibidores de tafla
ECSP21012498A (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
SV2011003855A (es) Heteroarilos sustituidos
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
CR20150432A (es) Estra-1,3,5 (10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CY1116384T1 (el) Παραγωγα σουλφαμιδιου ως αναστολεις tafia
BR112022012130A2 (pt) Compostos antelmínticos compreendendo uma estrutura azaindólica
UY30585A1 (es) Derivados de isoserina como inhibidores del factor ixa de la coagulacion
CL2020003331A1 (es) Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
MX2023006744A (es) Compuestos antihelminticos que comprenden una estructura de tienopiridina.
BR112022012126A2 (pt) Compostos antelmínticos compreendendo uma estrutura quinolínica
PA8597501A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
GT200500219A (es) 4-(2,4-dicloro-5-metoxifenil)amino-6-metoxi-7([5-amino-sustituido)metil]-3-furil)-3-quinolincarbonitrilos comoinhibidores de quinasa.
DOP2007000142A (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia